Abcam, ab258948, Human LXN (TCI) knockout HeLa cell lysate

Size: 1Kit
LXN KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon 1 and 8 bp deletion in exon 1 and Insertion of the selection cassette in exon 1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon 1 and 8 bp deletion in exon 1 and Insertion of the selection cassette in exon 1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-LXN, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LXN also known as Latexin or TCI (Tryptase Inhibitor Complex) is a protein with a molecular mass of approximately 24 kDa. LXN acts as an inhibitor of carboxypeptidase A and is primarily involved in regulating protease activity. It is expressed mainly in the liver lung and kidney playing a significant role in protein degradation processes. LXN's inhibitory functions contribute significantly to cellular processes by modulating enzyme activity.
Biological function summary
LXN influences cell proliferation and differentiation. It participates in cellular protection mechanisms against enzymatic damage and balances protease and anti-protease activities in tissues. Although not part of a large complex LXN impacts various cellular events through its protease inhibitor function making it important in tissue homeostasis. Studies suggest its importance in maintaining cell viability and regulating cellular stress responses.
Pathways
LXN associates with pathways linked to inflammation and tissue remodeling with particular emphasis on the protease-antiprotease balance. LXN acts within the kallikrein-kinin system and relates to proteins such as carboxypeptidase A1 which it directly inhibits. Its modulation of these pathways is essential for normal physiological responses and protective mechanisms against tissue damage.
LXN has been linked to cancer and inflammation-related conditions. In cancer its regulation of protease activity can influence tumor growth and metastasis often interacting with proteins like tryptase. LXN's role in inflammation relates to conditions such as rheumatoid arthritis where its influence on the balance of proteases and inhibitors impacts tissue damage and repair processes. Further research into LXN's roles may help elucidate mechanisms driving these diseases offering potential therapeutic targets.